Global News

[ad_1] Respiratory syncytial virus vial. Manjurul | Istock | Getty Images Vaccinating one million adults ages 65 and above with a single RSV shot from Pfizer or GSK may prevent thousands of hospitalizations over two seasons of the virus, according to a Centers for Disease Control and Prevention analysis .  A CDC medical officer presented the analysis, conducted by researchers at the University of Michigan, at an advisory committee meeting on Wednesday. The committee recommended that adults ages 60 and older may receive one dose of Pfizer's or GSK's respiratory syncytial virus shot after consulting their doctor.  The analysis found that vaccinating one million adults 65 and older with a single dose of Pfizer's shot may prevent 2,500 hospitalizations and 25,000 outpatient visits over two seasons of the virus. RSV season typically lasts from October to March in the Northern Hemisphere.   The analysis also found that vaccinating one million adults in the same age gr...

[ad_1] Nikos Pekiaridis | Nurphoto | Getty Images Stock Chart Icon Stock chart icon Novavax shares jump on news of a settlement payment from the Canadian government. It's unclear how many doses of Novavax's jab – its only commercially available product after 35 years – went unused. Under the amended agreement, Novavax will also provide Canada with fewer doses of its vaccine on a revised delivery schedule.  However, Canada can terminate the contract if Novavax fails to receive regulatory approval for vaccine production at the Canadian government's biomanufacturing facility by Dec. 31, 2024, according to the agreement. The announcement is another sign of hope for investors after the cash-strapped company raised doubts about its ability to stay in business earlier this year.  CNBC Health & Science Read CNBC's latest health coverage: In May, Novavax adopted a more positive outlook and announced a sweeping cost-cutting plan alongside its first-quarter earnings repor...